105-108, SMART VISION COMPLEX, HEALTHCARE ROAD, OPPOSITE HEALTHCARE COMPLEX. MUMBAI - 689578

www.drlogy.com

## Yash M. Patel

Age: 21 Years Sex: Male PID: 555



## Sample Collected At:

125, Shivam Bungalow, S G Road, Mumbai

iviuiiibai

Ref. By: Dr. Hiren Shah



Registered on: 02:31 PM 02 Dec, 2X Collected on: 03:11 PM 02 Dec, 2X Reported on: 04:35 PM 02 Dec, 2X

## **LIVER FUNCTION TEST (LFT)**

Investigation	Result		Reference Value	Unit
Primary Sample Type :	Serum			
AST (SGOT) IFCC without P5P	16.00		15.00 - 40.00	U/L
ALT (SGPT) IFCC without P5P	100.50	High	10.00 - 49.00	U/L
AST:ALT Ratio Calculated	0.50		<1.00	
<b>GGTP</b> IFCC	10.20		0 - 73	U/L
Alkaline Phosphatase (ALP)	15.40	Low	30.00 - 120.00	U/L
Bilirubin Total	0.60		0.30 - 1.20	mg/dL
Bilirubin Direct	0.10		<0.3	mg/dL
Bilirubin Indirect Calculated	0.10		<1.10	mg/dL
Total Protein	6.39		5.70 - 8.20	g/dL
Albumin BCG	2.00		3.20 - 4.80	g/dL
A : G Ratio Calculated	0.10		0.90 - 2.00	

## Note:

- 1. In an asymptomatic patient, Non alcoholic fatty liver disease (NAFLD) is the most common cause of increased AST, ALT levels. NAFLD is considered as hepatic manifestation of metabolic syndrome.
- 2. In most type of liver disease, ALT activity is higher than that of AST; exception may be seen in Alcoholic Hepatitis, Hepatic Cirrhosis, and Liver neoplasia. In a patient with Chronic liver disease, AST:ALT ratio>1 is highly suggestive of advanced liver fibrosis.
- 3. In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or NAFLD, Enhanced liver fibrosis (ELF) test may be used to evaluate liver fibrosis.
- 4. In a patient with Chronic Liver disease, AFP and Des-gamma carboxyprothrombin (DCP)/PIVKA II can be used to assess risk for development of Hepatocellular Carcinoma.

\*\*\*\*End of Report\*\*\*\*

Thanks for Reference

(DMLT, BMLT)

**Medical Lab Technician** 

**Dr. Payal Shah** (MD, Pathologist)

**Dr. Vimal Shah** (MD, Pathologist)

Generated on: 02 Dec, 202X 05:00 PM

Page 1 of 1



